IGF-1 LR3 1mg Canada

Technical Specifications

Compound Name: IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1)
Quantity: 1mg per vial
Format: Lyophilized peptide powder
Peptide Length: 83 amino acids (modified IGF-1 analogue)
Molecular Weight: Approximately 9200–9300 Da (approximate)
Purity Standard: ≥98% (HPLC, batch dependent)
Research Classification: Investigational peptide – laboratory research use only

IGF-1 LR3 1mg Canada is supplied as a lyophilized synthetic peptide intended exclusively for laboratory and analytical applications. Each vial contains 1 milligram of the modified insulin-like growth factor analogue prepared under controlled handling and quality verification standards appropriate for research material distribution.

This product is classified as an investigational research compound and is not authorized for therapeutic, diagnostic, or consumer use in Canada when supplied in research format.

Research Overview

IGF-1 LR3 is a modified analogue of endogenous insulin-like growth factor-1 (IGF-1). The LR3 designation refers to the substitution of arginine at position 3 and the extension of the peptide by 13 additional amino acids at the N-terminus. These structural modifications enhance receptor binding persistence and reduce affinity for certain binding proteins in experimental systems.

Research involving IGF-1 LR3 1mg Canada typically focuses on insulin-like growth factor receptor (IGF-1R) signalling, cellular proliferation pathways, and anabolic signalling cascades in laboratory environments. The scientific literature describes IGF-1 LR3 as a research tool for studying receptor activation kinetics and downstream intracellular signalling processes.

Preclinical studies have evaluated IGF-1 analogues in cell culture and animal models examining PI3K/Akt and MAPK/ERK pathways, which are associated with cell growth and metabolic regulation in experimental systems. Investigations often include gene expression analysis, receptor-binding assays, and signal-transduction profiling.

IGF-1 LR3 1mg Canada is supplied strictly for research purposes. All references to biological pathways reflect investigational findings and do not imply authorized clinical or therapeutic use of the research-grade material.

Mechanism Overview

IGF-1 LR3 functions in laboratory models as an agonist of the insulin-like growth factor-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor. Activation of IGF-1R stimulates autophosphorylation and initiates downstream signalling cascades involving PI3K/Akt and MAPK pathways in experimental systems.

Compared with native IGF-1, the LR3 modification reduces binding to IGF-binding proteins (IGFBPs), thereby increasing its bioavailability and the duration of receptor interaction in laboratory assays. Researchers studying IGF-1 LR3 1mg Canada typically measure receptor phosphorylation levels, transcription factor activation, and protein synthesis markers in controlled environments.

Mechanistic descriptions remain confined to preclinical and investigational data and are presented for educational purposes only.

Clinical Development Context

Native IGF-1 has been studied in various clinical research settings, and certain IGF-1–based pharmaceutical formulations have been authorized internationally for specific medical indications under prescription supervision.

However, IGF-1 LR3 1mg, supplied in research-grade format, is categorized as an investigational laboratory compound. It is distinct from authorized pharmaceutical preparations and is not approved by Health Canada as a prescription medication or consumer product when provided as a research material.

Scientific interest in IGF-1 analogues continues in endocrinology and cellular biology research institutions that examine growth factor signalling pathways.

Regulatory Status in Canada

IGF-1 LR3 1mg Canada is classified as an investigational research peptide. It is not authorized by Health Canada as a therapeutic drug, natural health product, or over-the-counter medication when supplied in research format.

The peptide is provided exclusively for laboratory and analytical purposes and is not intended for human or veterinary administration.

Handling, storage, and study of IGF-1 LR3 1mg Canada must comply with applicable Canadian federal and provincial regulations governing chemical and biological research materials. Laboratories and research institutions are responsible for maintaining regulatory compliance.

Molecular and Structural Notes

IGF-1 LR3 differs from endogenous IGF-1 by the substitution of arginine at position 3 and the addition of a 13-amino-acid N-terminal extension. These modifications increase resistance to binding protein sequestration and prolong receptor interaction in experimental models.

The peptide consists of 83 amino acids and has a molecular weight of approximately 9.2–9.3 kDa. Its tertiary structure includes disulphide bonds that stabilize the protein’s conformation, similar to that of native IGF-1.

IGF-1 LR3 1mg Canada is typically characterized using analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry to confirm identity and purity before distribution.

The lyophilized format supports peptide stability during storage when maintained under appropriate laboratory conditions.

Frequently Asked Questions

What is IGF-1 LR3 1mg Canada studied for in research?
IGF-1 LR3 1mg Canada is studied in laboratory settings to investigate IGF-1 receptor activation and growth factor signalling pathways.

Is IGF-1 LR3 approved for medical use in Canada? Health Canada does not authorize research-grade IGF-1 LR3 for therapeutic or consumer use. Approved pharmaceutical formulations are regulated separately.

What type of compound is IGF-1 LR3?
It is a modified analogue of insulin-like growth factor-1, studied in cellular signalling and endocrinology research.

Does IGF-1 LR3 1mg Canada contain additives?
Unless specified in the batch documentation, the vial contains only the lyophilized peptide compound.

Can IGF-1 LR3 1mg Canada be used outside research facilities?
No. It is supplied strictly for controlled laboratory and analytical research purposes.

Educational Disclaimer

IGF-1 LR3 1mg Canada is an investigational research peptide supplied solely for laboratory and analytical use. It is not approved by Health Canada as a medication, therapeutic agent, or consumer product when provided in research-grade form.

Information provided on this page is educational in nature and based on publicly available scientific literature describing investigational research contexts. No medical, diagnostic, or therapeutic claims are made.

Study and handling of IGF-1 LR3 1mg Canada should occur only within properly equipped research facilities and in accordance with applicable Canadian regulations and institutional guidelines.